GenEdit and Editas Medicine Enter into Exclusive License and Collaboration
Agreement for Nanoparticle Gene Therapy Delivery | Business Wire
GenEdit and Editas announce a worldwide, exclusive license and
collaboration to enable safer and more effective delivery of CRISPR-based
therapeutics.